Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference
Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, will participate in the Lake Street Capital Markets "BIG9" Conference on September 11, 2025 in New York City. The company's management will engage in one-on-one meetings with investors during the conference. No webcast will be available for this event due to its format.
Profound Medical (NASDAQ:PROF), azienda commerciale nel settore dei dispositivi medici specializzata in terapie di ablazione tissutale senza incisione, parteciperà alla Lake Street Capital Markets "BIG9" Conference l'11 settembre 2025 a New York City. Il management terrà incontri one-to-one con gli investitori durante la conferenza. A causa del formato dell'evento non sarà disponibile alcuna webcast.
Profound Medical (NASDAQ:PROF), una empresa de dispositivos médicos en fase comercial especializada en terapias de ablación tisular sin incisión, participará en la Lake Street Capital Markets "BIG9" Conference el 11 de septiembre de 2025 en la ciudad de Nueva York. La dirección mantendrá reuniones individuales con inversores durante la conferencia. No habrá webcast disponible debido al formato del evento.
Profound Medical (NASDAQ:PROF), 절개 없는 조직 소작 치료를 전문으로 하는 상업 단계 의료기기 기업이 Lake Street Capital Markets "BIG9" Conference에 2025년 9월 11일 뉴욕시에서 참가합니다. 경영진은 컨퍼런스 기간 동안 투자자들과 일대일 미팅을 가질 예정입니다. 행사 형식상 웹캐스트는 제공되지 않습니다.
Profound Medical (NASDAQ:PROF), une entreprise commerciale de dispositifs médicaux spécialisée dans les thérapies d'ablation tissulaire sans incision, participera à la Lake Street Capital Markets "BIG9" Conference le 11 septembre 2025 à New York. La direction tiendra des entretiens individuels avec des investisseurs pendant la conférence. Aucun webcast ne sera disponible en raison du format de l'événement.
Profound Medical (NASDAQ:PROF), ein kommerziell tätiges Medizintechnikunternehmen, das sich auf schnittfreie Gewebeablationstherapien spezialisiert hat, wird an der Lake Street Capital Markets "BIG9" Conference am 11. September 2025 in New York City teilnehmen. Das Management wird während der Konferenz Einzelgespräche mit Investoren führen. Wegen des Formats der Veranstaltung wird kein Webcast angeboten.
- None.
- None.
TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets “BIG9” Conference on September 11, 2025 in New York City.
The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When is Profound Medical (PROF) presenting at the Lake Street BIG9 Conference?
Will there be a webcast available for Profound Medical's Lake Street Conference presentation?
What type of company is Profound Medical (PROF)?
Where will the Lake Street BIG9 Conference with Profound Medical take place?
